Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | SELL | P14151 | 1/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | SELE | P16581 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30597490 | 0.88 | CYP3A4 (0.54) | CYP3A4MEN1KMT2AHPGDTHRB | |
| SCHEMBL2648126 | 0.88 | CYP3A4 (0.54) | CYP3A4MEN1KMT2AHPGDTHRB | |
| SCHEMBL24977344 | 0.84 | CYP3A4 (0.50) | CYP3A4MEN1KMT2AHPGDTHRB | |
| SCHEMBL30800461 | 0.84 | CYP3A4 (0.50) | CYP3A4MEN1KMT2AHPGDTHRB | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL105416 | 0.81 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AHPGDTHRB | |
| SCHEMBL4408095 | 0.81 | CYP3A4 (0.68) | CYP3A4MEN1KMT2AHPGDACHE | |
| SCHEMBL29788586 | 0.81 | CYP3A4 (0.68) | CYP3A4MEN1KMT2AHPGDACHE | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL564755 | 0.79 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AHPGDTHRB | |
| SCHEMBL632446 | 0.79 | CYP3A4 (0.58) | CYP3A4MEN1KMT2AHPGDACHE | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL1421619 | 0.79 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AHPGDTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720050-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249672-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| US-12091389-B2 | Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1 | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20230133011-A1 | MULTIFUNCTIONAL CYTOPROTECTANT FOR TREATMENT OF PATHOGENIC PROCESSES MEDIATED BY OXIDATIVE STRESS AND TOXIC ELECTROPHILES | MONTEFIORE MEDICAL CENTER (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-20050043300-A1 | Piperazine derivatives | PFIZER INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011592-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
| EP-0850948-B1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6048842-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0850948-A1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0104018-A2 | Benzopyran, benzothiapyran and quinoline compounds and pharmaceutical compositions containing them | FISONS plc (GB) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032711-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | CYP3A4 590/4885MEN1 4086/4885KMT2A 4478/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | CYP3A4 943/4885MEN1 1596/4885KMT2A 635/4885 |
| US-12091389-B2 | Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1 | GPR18, TRPV1, TRPV3 | CYP3A4 2832/4885MEN1 3821/4885KMT2A 4004/4885 |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A2, SLC5A1, UGGT1 | CYP3A4 149/4885MEN1 3350/4885KMT2A 4498/4885 |
| US-20050043300-A1 | Piperazine derivatives | CD4, CCR5, RRP15 | CYP3A4 140/4885MEN1 4800/4885KMT2A 2921/4885 |
| US-20230133011-A1 | MULTIFUNCTIONAL CYTOPROTECTANT FOR TREATMENT OF PATHOGENIC PROCESSES MEDIATED BY OXIDATIVE STRESS AND TOXIC ELECTROPHILES | GPX4, TXN2, PRDX5 | CYP3A4 3563/4885MEN1 4612/4885KMT2A 4797/4885 |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | CYP3A4 1311/4885MEN1 3585/4885KMT2A 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.